Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-009696
Filing Date
2021-05-10
Accepted
2021-05-10 16:12:01
Documents
89
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20210331.htm   iXBRL 10-Q 2172873
2 EX-10.4 exhibit104-q12021.htm EX-10.4 174533
3 EX-10.5 exhibit105-q12021.htm EX-10.5 436025
4 EX-31.1 exhibit311-q12021.htm EX-31.1 11356
5 EX-31.2 exhibit312-q12021.htm EX-31.2 11379
6 EX-32.1 exhibit321-q12021.htm EX-32.1 9248
  Complete submission text file 0001628280-21-009696.txt   10545811

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20210331.xsd EX-101.SCH 93127
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20210331_cal.xml EX-101.CAL 119028
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20210331_def.xml EX-101.DEF 450990
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20210331_lab.xml EX-101.LAB 814241
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20210331_pre.xml EX-101.PRE 601690
12 EXTRACTED XBRL INSTANCE DOCUMENT akba-20210331_htm.xml XML 1503264
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 21907288
SIC: 2834 Pharmaceutical Preparations